So sánh hiệu quả của alendronate và acid zoledronic trong việc cải thiện khối lượng xương ở bệnh nhân thalassemia phụ thuộc truyền máu

Maheri A, Sadeghi R, Shojaeizadeh D, Tol A, Yaseri M, Ebrahimi M (2016) Associations between a healthpromoting lifestyle and quality of life among adults with beta-thalassemia major. Epidemiol Health 38 Dhirar N, Khandekar J, Bachani D, Mahto D (2016) Thalassemia major: how do we improve quality of life? SpringerPlus 5:1895 Hassan MAM, Tolba OA (2016) Iron chelation monotherapy in transfusion-dependent beta-thalassemia major patients: a comparative study of deferasirox and deferoxamine. Electron Phys 8:2425 Giusti A (2014) Bisphosphonates in the management of thalassemia-associated osteoporosis: a systematic review of randomised controlled trials. J Bone Miner Metab 32:606–615 Morabito N, Gaudio A, Lasco A, Atteritano M, Pizzoleo MA, Cincotta M, La Rosa M, Guarino R, Meo A, Frisina N (2004) Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle. J Bone Miner Res 19:722–727 Gaudio A, Morabito N, Xourafa A, Macri I, Meo A, Morgante S, Trifiletti A, Lasco A, Frisina N (2008) Bisphosphonates in the treatment of thalassemia-associated osteoporosis. J Endocrinol Investig 31:181–184 Gilfillan C, Strauss B, Rodda C, Bowden D, Kean A-M, Obaid M, Crawford B (2006) A randomized, double-blind, placebo-controlled trial of intravenous zoledronic acid in the treatment of thalassemia-associated osteopenia. Calcif Tissue Int 79:138–144. https://doi.org/10.1007/s00774-019-01003-1 Voskaridou E, Terpos E, Spina G, Palermos J, Rahemtulla A, Loutradi A, Loukopoulos D (2003) Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. Br J Haematol 123:730–737 Tsartsalis AN, Lambrou GI, Tsartsalis D, Savvidis C, Karantza M, Terpos E, Kanaka-Gantenbein C, Chrousos GP, Kattamis A (2018) The role of biphosphonates in the management of thalassemia-induced osteoporosis: a systematic review and metaanalysis. Hormones 1–14 Voskaridou E, Terpos E (2004) New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. Br J Haematol 127:127–139 Sarrai M, Duroseau H, D‘Augustine J, Moktan S, Bellevue R (2007) Bone mass density in adults with sickle cell disease. Br J Haematol 136:666–672 Ravn P, Weiss SR, Rodriguez-Portales JA, McClung MR, Wasnich RD, Gilchrist NL, Sambrook P, Fogelman I, Krupa D, Yates AJ (2000) Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. J Clin Endocrinol Metab 85:1492–1497 Rosen CJ, Gallagher JC (2011) The 2011 IOM report on vitamin D and calcium requirements for north america: clinical implications for providers treating patients with low bone mineral density (in eng). J Clin Densitom 14:79–84. https://doi.org/10.1016/j.jocd.2011.03.004 Lim JU, Lee JH, Kim JS, Hwang YI, Kim TH, Lim SY, Yoo KH, Jung KS, Kim YK, Rhee CK (2017) Comparison of World Health Organization and Asia-Pacific body mass index classifications in COPD patients. Int J Chron Obstruct Pulmon Dis 12:2465–2475. https://doi.org/10.2147/copd.s141295 De Sanctis V, Soliman AT, Elsefdy H, Soliman N, Bedair E, Fiscina B, Kattamis C (2017) Bone disease in β thalassemia patients: past, present and future perspectives. Metabolism Terpos E, Voskaridou E (2010) Treatment options for thalassemia patients with osteoporosis. Ann N Y Acad Sci 1202:237–243 Jensen C, Tuck S, Agnew J, Koneru S, Morris R, Yardumian A, Prescott E, Hoffbrand A, Wonke B (1998) High prevalence of low bone mass in thalassaemia major. Br J Haematol 103:911–915 Duan Y, De Luca V, Seeman E (1999) Parathyroid hormone deficiency and excess: similar effects on trabecular bone but differing effects on cortical bone. J Clin Endocrinol Metab 84:718–722 Orwoll ES, Miller PD, Adachi JD, Brown J, Adler RA, Kendler D, Bucci-Rechtweg C, Readie A, Mesenbrink P, Weinstein RS (2010) Efficacy and safety of a once-yearly iv infusion of zoledronic acid 5 mg versus a once–weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res 25:2239–2250 Perrotta S, Cappellini MD, Bertoldo F, Servedio V, Iolascon G, D'agruma L, Gasparini P, Siciliani MC, Iolascon A, (2000) Osteoporosis in β- thalassaemia major patients: analysis of the genetic background. Br J Haematol 111:461–466. https://doi.org/10.1007/s00774-019-01003-1 Pollak RD, Rachmilewitz E, Blumenfeld A, Idelson M, Goldfarb AW (2000) Bone mineral metabolism in adults with β-thalassaemia major and intermedia. Br J Haematol 111:902–907 Saag K, Lindsay R, Kriegman A, Beamer E, Zhou W (2007) A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone 40:1238–1243 Shirani F, Shahriari-Ahmadi A, Arabi M, Asefi N (2015) Evaluation of alendronate efficacy on bone mineral density in thalassemic patients. Int J Hematol-Oncol Stem Cell Res 6:20–24 Morabito N, Lasco A, Gaudio A, Crisafulli A, Di Pietro C, Meo A, Frisina N (2002) Bisphosphonates in the treatment of thalassemia-induced osteoporosis. Osteoporos Int 13:644–649 Boonen S, Orwoll E, Magaziner J, Colón-Emeric CS, Adachi JD, Bucci-Rechtweg C, Haentjens P, Kaufman JM, Rizzoli R, Vanderschueren D (2011) Once-yearly zoledronic acid in older men compared with women with recent hip fracture. J Am Geriatr Soc 59:2084–2090 McClung M, Miller P, Recknor C, Mesenbrink P, Bucci-Rechtweg C, Benhamou CL (2009) Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial. Obstet Gynecol 114:999–1007. https://doi.org/10.1097/AOG.0b013e3181bdce0a Perifanis V, Vyzantiadis T, Tziomalos K, Vakalopoulou S, Garipidou V, Athanassiou-Metaxa M, Harsoulis F (2007) Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia. Ann Hematol 86:23–30 Voskaridou E, Christoulas D, Konstantinidou M, Tsiftsakis E, Alexakos P, Terpos E (2008) Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial. Haematologica 93:1588–1590 Otrock ZK, Azar ST, Shamseddeen WA, Habr D, Inati A, Koussa S, Mahfouz RA, Taher AT (2006) Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial. Ann Hematol 85:605–609 Piscitelli P, Auriemma R, Neglia C, Migliore A (2014) Alendronate: new formulations of an old and effective drug to improve adherence avoiding upper gastrointestinal side effects. Eur Rev Med Pharmacol Sci 18:3788–3796